CA2870690A1 — Treatment of preadolescent moderate acne vulgaris
Assigned to Galderma Research and Development SNC · Expires 2013-11-28 · 12y expired
What this patent protects
The present invention concerns a method of treating preadolescent acne, which comprises administering an effective amount of a pharmaceutical composition comprising a fixed combination of adapalene and benzol peroxide to a preadolescent patient in need thereof. According to the i…
USPTO Abstract
The present invention concerns a method of treating preadolescent acne, which comprises administering an effective amount of a pharmaceutical composition comprising a fixed combination of adapalene and benzol peroxide to a preadolescent patient in need thereof. According to the invention, the preadolescent patient is from age 7 to age 11, and the pharmaceutical composition comprises from 0.01% to 2% by weight of adapalene and from 0.1 to 5% by weight by weight of benzol peroxide. The present invention also concerns a composition for use in such a method.
Drugs covered by this patent
- Differin (ADAPALENE) · Galderma Labs Lp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.